Medical Sciences Divisional Office
University of Oxford
Level 3, John Radcliffe Hospital
Oxford OX3 9DU
Head of Medical Sciences Division
The Head of Division is responsible for maintaining and further developing the international reputation of Medical Sciences in both research and teaching. He provides vision and leadership across all aspects of the Division's activities including divisional research strategy, educational policy and standards, the recruitment and retention of outstanding academics, relationships with external funding agencies, interactions with local NHS Foundation Trusts, fundraising, improving diversity and equality, and the use of resources. He works closely with the heads of the 16 departments within the Division and the other University academic divisions to foster strong interdisciplinary links across the spectrum of academic activity and with the colleges to help maintain excellence in teaching for undergraduate and graduate courses.
The Head of Division is a member of University Council and its major committees, which are responsible for determining overall university strategy.
Prior to being appointed as the Head of the Medical Sciences Division, Professor Screaton was Dean of the Faculty of Medicine, Imperial College.
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
Tuekprakhon A. et al, (2022), Cell
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Shaw RH. et al, (2022), The Lancet. Respiratory medicine
Evolution of long-term hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study
Moore S. et al, (2022)
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
Liu X. et al, (2022), The Journal of infection, 84, 795 - 813
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18